BioMarin Pharmaceutical Inc
BMRN
查看详细走势图
58.130USD
+0.980+1.71%
收盘 02/06, 16:00（美东）报价延迟15分钟
11.17B总市值
21.38市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.71%
5天
+2.81%
1月
-5.19%
6月
-2.24%
今年开始到现在
-2.19%
1年
-9.07%
查看详细走势图
TradingKey BioMarin Pharmaceutical Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
BioMarin Pharmaceutical Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名43/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价90.89。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
BioMarin Pharmaceutical Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
BioMarin Pharmaceutical Inc亮点
亮点风险
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
业绩高增长
公司营业收入稳步增长，连续3年增长36.16%
利润高增长
公司净利润处于行业前列，最新年度总收入2.85B美元
估值低估
公司最新PE估值21.38，处于3年历史低位
机构加仓
最新机构持股187.90M股，环比增加0.04%
ETHSX持仓
明星投资者ETHSX持仓，最新持仓市值17.35K
分析师目标
根据
26
位分析师
买入
评级
92.472
目标均价
+60.49%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BioMarin Pharmaceutical Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BioMarin Pharmaceutical Inc简介
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
公司代码BMRN
公司BioMarin Pharmaceutical Inc
CEOHardy (Alexander)
网址https://www.biomarin.com/
相关品种
